



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/299,562	04/27/1999	LAJOS HEGEDUS	3347-101P	3425

26646 7590 04/08/2003

KENYON & KENYON
ONE BROADWAY
NEW YORK, NY 10004

[REDACTED] EXAMINER

WEGERT, SANDRA L

[REDACTED] ART UNIT [REDACTED] PAPER NUMBER

1647

DATE MAILED: 04/08/2003

Q4

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/299,562	HEGEDUS ET AL.
	Examiner Sandra Wegert	Art Unit 1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any named patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 21 January 2003.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 24-29, 91, 92 and 95 is/are pending in the application.

4a) Of the above claim(s) 24-29, 91 and 92 is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 95 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input checked="" type="checkbox"/> Interview Summary (PTO-413) Paper No(s). <u>24</u> .
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .	6) <input type="checkbox"/> Other: _____

DETAILED ACTION

Status of Application, Amendments, and/or Claims

A Request for Continued Examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. This application is eligible for continued examination under 37 CFR 1.114, since the fee set forth in 37 CFR 1.17(e) has been timely paid. Applicant's submission filed on 27 January 2003 (Paper 22) has been entered. The Preliminary Amendment, sent 27 January 2003, has been entered as Paper 23. Claims 30-37, 42-90 and 93-94 were cancelled. Claim 95 was added and reads on the elected Invention. Claims 91 and 92 have been withdrawn by the Examiner as being drawn to a non-elected Invention.

Claim 95 is under examination in the current application.

Claim Rejections/Objections

Claim Objections-

Claim 95 is objected to for depending from a cancelled claim.

Appropriate correction is required.

35 USC § 102- Prior Art

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 95 is rejected under 35 USC 102(b), as being anticipated by Satoh, et al, (EPO 0326618, 7 September 1988). Satoh, et al teach a pharmaceutical composition comprising a poorly-soluble drug that is known to bind protein, said drug attached by non-covalent binding to albumin. Similar to the claim of the instant Application, the Satoh, et al reference discloses a method of making the pharmaceutical composition by distillation of the solvent.

The Instant Claim makes no mention of properties that distinguish the claimed compositions from those disclosed in the EPO 0326618 patent (Satoh, 1988), for example: the concentrations of the drugs and plasma proteins listed in examples II.1- II.5 of the instant Specification (e.g., 1.2×10^{-4} M to 1.5×10^{-4} M for albumin and γ -globulin, respectively), the method steps listed in Examples II.1- II.5 of the instant Specification, and the detailed steps by which the formulation is made.

Claim Rejections - 35 USC § 112, second paragraph-indefiniteness.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 95 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 95 is rendered indefinite because it is organized in such a way that it appears that the “aqueous solution” both *is* the formulation and is a member of a list of ingredients comprising the formulation. Applicants should amend the claim to insure that part 95(i) is a member of the list comprising the formulation (for example: “*i*) *an aqueous solvent*, *ii*) *a therapeutically-active drug*”, etc.) or should amend the claim to make it more clear that the formulation *is* an aqueous solution (“An aqueous pharmaceutical solution comprising”, etc).

Conclusion:

Claim 95 is rejected for the reasons listed above.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Wegert whose telephone number is (703) 308-9346. The examiner can normally be reached Monday - Friday from 9:30 AM to 6:00 PM (Eastern Time). If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Gary Kunz, can be reached at (703) 308-4623.

Art Unit: 1647

Official papers filed by fax should be directed to (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

SLW

4/4/03

Elizabeth C. Bernmeier